In summary, we discovered a five-mRNA signature (PTPRN, NMB, RALYL, ABCC3, and MDK) among hundreds of potential mRNAs in large-scale GBM samples that can be employed as an independent prognostic marker in stratifying risk subgroups for GBM survival. This evidence concerns the gene RALYL and glioblastoma.